

REMARKS

Upon entry of this Preliminary Amendment, claims 1-10 and 14 are pending. An Abstract on a separate sheet is attached as required under 37 CFR 1.72(b). Claims 11-13 has been cancelled. Claims 3-7, 10 and 14 have been amended to eliminate multiple dependencies and to conform the claim set to the proper U.S. format.

Entry of this amendment into the record is requested.

Respectfully submitted,



Laura K. Madden
Agent for Applicants
Registration No. 48,352

GLAXOSMITHKLINE
Corporate Intellectual Property-UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone: (610) 270-7339
Facsimile: (610) 270-5090
n:\lkm\p30000\p31779-C3\preliminary amendment.doc

ABSTRACT OF THE DISCLOSURE

Hydrated N-[3-[[2-(3,4-dimethoxyphenyl)ethyl]amino]propyl]-4-nitro benzamide hydrochloride characterised in that it:

- (i) comprises water in the range of from 1.7 to 2.4 molar equivalents; and/or
- (ii) has a melting point above 145°C and/or
- (iii) provides an infra red spectrum containing peaks at 3510, 3342, 3076, 1665, 1598, 1343, 1330, 1216 and 801 cm^{-1} ; and/or
- (iv) provides a solid state nuclear magnetic resonance spectrum containing chemical shifts substantially as represented in Table I; and/or
- (v) provides an X-ray powder refraction (XRPD) pattern substantially as represented in Table II; a process for preparing such a compound, a pharmaceutical composition comprising such a compound and the use of such a compound in medicine.